

Special Issue

Hereditary and Familial Colorectal Cancer

Message from the Guest Editors

Hereditary and familial colorectal cancers represent nearly a quarter of all colorectal cancers diagnosed. This is caused by identifiable pathogenic germline variants in colorectal cancer risk genes, leading to known hereditary colorectal cancer risk syndromes such as Lynch syndrome or familial adenomatous polyposis (FAP), or may be also related to other familial factors that are less well defined. Identification of and germline genetic testing for these high-risk individuals and families is of paramount importance in terms of allowing for syndrome identification and risk stratification. Finally, cancer prevention through lifestyle modifications and chemoprevention may have a substantial impact on future cancer risk. This Special Issue of *Cancers* will be focused on hereditary and familial colorectal cancer, with a focus on identification of high-risk individuals and families, genetic testing, risk assessment, screening implementation and outcomes, and cancer prevention.

Guest Editors

Dr. Bryson W. Katona

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Dr. Peter P. Stanich

The Ohio State University Wexner Medical Center, Columbus, OH, USA

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/193810

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)